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We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide
vaccine (23-PPV) on pulmonarymucosal immunoglobulin levels. Bronchoalveolar lavage (BAL) and serum
were collected from 33 adults before and 1month after injected (n=16) or inhaled (n=17) 23-PPV. Levels
of pneumococcal capsule-speciﬁc IgGand IgA to types1, 9Vand14weremeasured in each sample. Injected
23-PPV produced a signiﬁcant increase in types 1, 9V and 14 capsule-speciﬁc IgG and type 1 IgA in both
serum and BAL (type 1 geometric mean BAL IgG 9.8ng/ml post-vaccine vs. 5ng/ml pre-vaccine, p=0.01;
type 9V geo mean 5.6ng/ml vs. 2.7ng/ml, p=0.001; type 14 geo mean 23.6ng/ml vs. 6.2ng/ml, p=0.02).
Inhaled vaccine produced no response in either BAL or serum.
© 2008 Elsevier Ltd. Open access under CC BY license.
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. Introduction
Streptococcus pneumoniae is the most common cause of pneu-
onia world-wide [1] as well as being a major cause of invasive
isease syndromes, such as bacteraemia and meningitis, and
ucosal syndromes such as otitis media and sinusitis [2]. The bur-
en of pneumonia [3] and bacterial meningitis [4] are particularly
igh in Africa, where the incidence and severity of these infec-
ions is greatly increased in young children and among patients
lso infected with the human immunodeﬁciency virus (HIV) [5,6].
ucosal syndromes are common in developed nations where oti-
ismedia is a particular problem among young children in day-care
nd pneumonia is a common cause of death in the elderly.
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Open access under CC BY license.Vaccination against pneumococcal infection has been an impor-
ant goal for many years with much effort focused on the
neumococcal polysaccharide capsule which is a major virulence
actor for the bacteria [7]. Pneumococcal carriage and disease are
nown to induce host immunity against recurrent infection with
he same capsular type (90 types have been described) both in
mmunocompetent adults and HIV infected adults [8]. This immu-
ity has been assumed to be due to the production of opsonic
ntibody speciﬁc to the pneumococcal capsular polysaccharide
ecause early passive transfer experiments demonstrated protec-
ion in animal experiments and serum therapy was used as a
herapy for pneumococcal disease in the pre-antibiotic era [9].
ncreased levels of capsule-speciﬁc antibody have been noted in
oth serum and lung ﬂuid following pneumococcal disease in both
mmunocompetent and HIV infected adults [10]. The ﬁrst pneumo-
occal vaccine trials usedwhole dead bacteria [11] quickly followed
y puriﬁed capsular polysaccharide. This induced anti-capsular
ntibody, predominantly IgG, and serum levels of immunoglobu-
in have been used as a surrogate measure of clinical protection.
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he ﬁrst pneumococcal polysaccharide vaccines were effective at
educingdisease ingroupsathigh riskof transmission, suchasmine
orkers [12] ormilitary recruits, butwere ineffective in young chil-
ren [13] andHIV infected adults [14]. In addition, it was noted that
ot only was the 23-valent pneumococcal polysaccharide vaccine
23-PPV) ineffective at preventing pneumonia in adults, but that it
ctually caused an excess of pneumonia in several randomized tri-
ls [15]. This excess of pneumonia reached statistical signiﬁcance
n trials involving both HIV infected adults [14] and elderly peo-
le [16]. The 23-PPV vaccine continues to be recommended in the
lderly and other adult groups at risk of pneumococcal disease,
owever, as it does offer protection against invasive pneumococcal
isease [17].
The paradox surroundingpneumonia in 23-PPVvaccinationwas
ecently overshadowed by the major success of the 7-valent pneu-
ococcal conjugate vaccine (7-PCV) which has already resulted in
n important reduction in pneumococcal disease in the USA [18]. A
imilar 9-valent vaccine has been shown to prevent pneumococcal
nfections in both HIV infected and healthy children in South Africa
19] and the Gambia [20], and has shown a signiﬁcant reduction
n all-cause mortality in vaccinated children in the Gambia study.
onjugate vaccines are also substantially less effective, however, at
reventing pneumonia than invasive pneumococcal disease [21].
he prevention of pneumonia is an important priority in pneumo-
occal vaccination as the number of cases of pneumonia is more
han double the combined total of bacteraemia andmeningitis [18].
We have addressed the hypothesis that vaccination may differ
rom native disease in that vaccination may fail to induce ade-
uate levels of protective pulmonary mucosal immunoglobulin.
ulmonaryhumoral responsesare locally regulatedas illustratedby
he poor correlation betweenpulmonary and systemic levels of cel-
ular inﬂammation [22] and immunoglobulin response [23] to both
nhaled antigen and pulmonary infection. We showed that speciﬁc
nti-pneumococcal capsular polysaccharide responses in lung ﬂuid
ollowingpneumococcal infectionwere regulated independently of
esponses seen in the serum, and that these responses were pre-
erved in HIV infected subjects [10]. Further, we also showed that
lthough conjugate vaccination resulted in increased pneumococ-
al capsule-speciﬁc immunoglobulin in lung ﬂuid from both HIV
nfected and immunocompetent adults [24], the immunoglobulin
unction was impaired in HIV infected subjects [25].
Two recent studies have shown that inhaled 23-PPV resulted
n a detectable serum response in healthy volunteers [26] and
atients with chronic obstructive pulmonary disease [27] but
ulmonary responses were not measured. We compared the pul-
onarymucosal responses to subcutaneous and inhaled 23-PPV to
etermine if the inhaled route offered any advantage in protecting
he mucosal surface.
. Methods
.1. Subject recruitment and selection
Adult volunteers with no history of pneumonia or asthma and a
ormal chest X-ray were recruited by advertisement in the Queen
lizabeth Central Hospital, Malawi. All volunteers gave written
nformed consent to HIV testing, histamine challenge test and par-
icipation in a single-blind trial of injected vs. inhaled 23-valent
neumococcal polysaccharide vaccine.
Initially, volunteers consented to HIV testing. We wished toxclude HIV positive volunteers as the 23-valent pneumococcal
olysaccharide vaccine (23-PPV) has been shown in a double-blind
andomized controlled trial to be harmful in HIV-infected subjects
14].HIVnegative volunteers carriedout amodiﬁedhistamine chal-
enge test to exclude subjects with latent asthma [28]. Subjects
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nhaled increasing numbers of breaths of saline and then 8mg/ml
istamine from 1 breath to amaximum of 32 breaths with 3 forced
xpiration in one second (FEV1) blowing tests after each dose. The
est was discontinued if the volunteer experienced either respira-
ory symptoms or a 15% reduction from baseline FEV1. This test
xcluded mild asthma patients after 4–8 breaths of histamine; all
ubjects proceeding to the vaccine study were able to inhale 32
reaths of 8mg/ml histamine without a 15% drop in FEV1.
This study was given ethical approval by the Liverpool School
f Tropical Medicine Research Ethics Committee and the College of
edicine Research Ethics Committee of the University of Malawi.
.2. Bronchoscopy and bronchoalveolar lavage (BAL)
Bronchoscopy and bronchoalveolar lavage was carried out at
aseline and at 1month after vaccination on all subjects and serum
as stored at each visit. Lavage samples (BAL) were collected as
reviously described [29]. Brieﬂy, topical lignocaine was applied
o nasal and pharyngeal mucosa in semi-recumbent subjects. A
ber-optic bronchoscope (Olympus, UK) was passed to the level of
sub-segmental bronchus of the right middle lobe and four 50ml
liquots of sterile normal saline at 37 ◦C instilled and removedusing
entle hand suction. The aspiratedbronchoalveolar lavageﬂuidwas
laced into siliconised glass containers and transferred immedi-
tely to the laboratory for processing within 30min. BAL samples
ere spun to obtain a cell pellet and the supernatant ﬂuid stored
n multiple aliquots at −80 ◦C for subsequent analysis by ELISA.
.3. Allocation to subcutaneous or inhaled vaccine (23-PPV)
Subjects listed by date of recruitment in separate gender lists
ere alternately allocated either inhaled or subcutaneous vaccine.
ll subjects and clinic staff were unaware of the allocation of any
ubject, and all subjects received both inhalations and an injection.
ubjects randomized to receive subcutaneous vaccine received3ml
f nebulised saline bymouth inhalation ondays 1 and2 and a0.5ml
3-PPV injection was given subcutaneously on day 2. Subjects ran-
omized to receive inhaled vaccine received 3ml nebulised saline
ontaining50l 23-PPV (1/10of avaccine)byoral inhalationonday
and 3ml of nebulised saline containing 0.5ml 23-PPV (a whole
accine) by oral inhalation on day 2. A sham injection of saline was
lso given subcutaneously on day 2. The technicians carrying out
he inhalations and FEV1 tests, and the nurses giving the injections
ndrecordingside-effectswereunawareofwhether the inhalations
r injection contained active vaccine for each patient. All patients
arried out check FEV1 measurements 10, 30, 60 and 180min after
ll inhalations.
.4. Nebulised delivery of 23-PPV
A simple jet nebuliser was selected (HS860 reuseable
idestream, Respironics, USA) to nebulise the vaccine asmore com-
lex piezo-electric systems (MicroAir, Omron, UK) became blocked
y the vaccine. The same nebuliser cup and source of pressur-
zed air was used for all participants [30]. The size of the inhaled
articles generated by the nebuliser expressed as the median
ass aerosol diameter (MMAD) for 23-PPV in this nebuliser was
easured using a low-ﬂow cascade impactor in two complete tri-
ls using sodium ﬂuoride impaction on to ﬁlters. Separately, the
ntegrity of the vaccine post-nebuliser was conﬁrmed by condens-
ng a nebulised vaccine and measuring the 23-PPV concentration
y sandwich ELISA. Brieﬂy, rabbit type1 serum (Statens Serumin-
titut, Denmark) was used as the capture antibody, with pooled
uman immune serum as the detection antibody and alkaline
hosphatase conjugated goat anti-human IgG as the secondary
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ntibody. After checker-board conﬁrmation of optimal ELISA condi-
ions, 23-PPV solution and condensed post-nebuliser aerosol were
ompared at eight serial dilutions. Finally, the distribution of the
accine between the eight different nebulised fractions in the cas-
ade impactor was compared by measuring the concentration of
3-PPV eluted from impact ﬁlters.
.5. ELISA measurement of pneumococcal capsule-speciﬁc IgG
nd IgA
All samples for ELISA measurement of pneumococcal capsule-
peciﬁc IgG and IgA were pre-adsorbed using CPS and 22f adsorp-
ion steps [31] in order to remove non-functional immunoglobulin.
capsular polysaccharide-speciﬁc capture ELISA was carried out
sing type 1, type 9V and type 14 capsular polysaccharide to mea-
ure vaccine-speciﬁc responses (American Type Culture Collection
ATCC), Manassas, USA). These are strains that elicit a range of anti-
ody responses following natural exposure and commonly cause
isease in our area. Alkaline phosphatase conjugated anti-human
gG or IgA (Sigma, UK) were used as secondary antibodies and
neumococcal Standard Serum, Lot 89-S (Center for Biological Eval-
ation and Review, Food and Drug Administration, Bethesda, MD;
indly donatedbyDrCarl Frasch)wasused as the standard. All sam-
les were run in triplicate in four dilutions, and samples with a CV
f greater than 15% were repeated.
.6. Sample size and data analysis
The studydesignassumed that a threefold increase in serum lev-
ls of capsule-speciﬁc immunoglobulin level would be measured
n response to vaccine in all subjects, and that the range of values
btained would be similar to those in earlier studies [10]. Using
hese assumptions, a sample size of 15 subjects per group was pre-
icted to be sufﬁcient to have more than 99% power to detect a
ifference in post-vaccination immunoglobulin level at the 5% sig-
iﬁcance level. We planned to recruit 17 subjects to each group to
llow for voluntary subject withdrawal from the study prior to the
econd bronchoscopy.
Clinical and experimental data were entered and checked using
n anonymisedMicrosoft Access database, and transferred to Stata
ersion 8 (Statacorp, USA) for analysis. Data were initially plot-
ed by test group (subcutaneous vs. inhaled vaccine) using box
lots. Baseline values were conﬁrmed to be matched by non-
aired t-tests on log transformed data (if Shapiro Wilks testing
howed that log transformed data did not follow a normal dis-
ribution, the two-sample Wilcoxon test was used). Levels of
apsule-speciﬁc IgG and IgA for three serotypes were then com-
ared within subject using paired t-test on log transformed data to
est for a signiﬁcant effect of vaccination in both serum and BAL.
f log transformed data did not form a normal distribution, paired
omparisons of before and after vaccination levels of immunoglob-
t
t
s
a
a
able 1
ubject details by route of vaccination
ntervention Injected vaccine
16
ge in years (S.D.) 31.6 (12.2)
ender (M:F) 11:5
revious pneumonia or vaccine 0
EV1 in litres (S.D.) 2.7 (0.44)
AL volume before vaccine in ml (S.D.) 118 (25.9)
AL volume after vaccine in ml (S.D.) 112 (21.9)
AL cells before vaccine (S.D.) 1.02×107 (7.1×106)
AL cells after vaccine (S.D.) 2.81×107 (1.5×107)6 (2008) 5400–5406
lin were made using paired non-parametric tests (sign rank test,
tata8).
. Results
.1. Subjects and samples
Thirty-three volunteers were selected and all completed the
tudy. None was a current or ex-smoker of cigarettes and none
ad any history of pulmonary disease. Demographic characteris-
ics, data from FEV1 testing and the results of bronchoalveolar
avage are summarised in Table 1. There were no signiﬁcant dif-
erences in the age, gender distribution or FEV1 of the groups. The
roup randomized to receive injected vaccine had a lower mean
AL recovery volume at both bronchoscopies than the group ran-
omized to receive inhaled vaccine. There were no side effects of
ronchoscopy in either group and adequate samples were recov-
red from all participants. The mean BAL recovery volume was
ower in the second bronchoscopy than the ﬁrst for both groups.
n addition, the cell count was increased in second bronchoscopy
ompared to the ﬁrst, consistent with a pro-inﬂammatory effect of
ronchoscopy but the increment in BAL volume and cell countwere
ot different between the injected and inhaled vaccine groups.
.2. Side-effects of injected and inhaled vaccine
Twenty-eight subjects reported minor side-effects of vaccina-
ionbut therewereno serious adverse events in this study. Fourteen
ubjects receiving subcutaneous vaccine reported side-effects
ncluding pain at the injection site (n=9, of whom two required
ydrocortisone cream), general malaise (n=3) and headache.
welve subjects receiving inhaled vaccine reported side-effects
ncluding dry mouth, distended abdomen, headache, diarrhea,
izziness and chills. Two subjects reported injection site pain after
lacebo injection.
.3. Nebuliser output
The nebuliser produced a range of particle sizes in a normal dis-
ributionwith amedian aerosol diameter (MMAD) of 2m(2.3m
nd 1.8m in two trials with the distribution shown in detail in
he on-line supplement). This particle size is consistent with alve-
lar deposition. Using a capture ELISA method (calibration curve
2 =0.98), measurements of post-nebulised fractions were shown
o have the same concentration of polysaccharide as new vaccine.
3-PPV concentration was measured after elution of impact ﬁl-
ers from 0.5ml of nebulised vaccine. The quantity of vaccine in
he top and next two fractions (very small particle size) was too
mall tomeasure. The next four fractions (these sizes are respirable
nddeposited in alveoli) all containeddetectable vaccine estimated
t 0.026, 0.073, 0.116 and 0.0123ml of vaccine. We therefore con-
Inhaled vaccine Difference, p
17
29.8 (8.1) 0.6
13:4 0.6
0
3.1 (0.84) 0.1
136 (11.4) 0.01
128 (12.9) 0.01
1.06×107 (6.3×106) 0.8
2.59×107 (1.1×107) 0.65
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Fig. 1. Comparison of serum responses to injected and inhaled vaccination with 23-valent pneumococcal capsular polysaccharide vaccine. IgG (left hand graphs) and IgA
(right hand graphs) speciﬁc to pneumococcal capsular types 1, 9V and 14 are shown before and 1 month after vaccine. The box (25–75%) and whisker (5–95%) graphs with
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ested was seen at 1 month. There was a signiﬁcant increase seen in type 1 IgA only.
here was a signiﬁcant drop in both IgG and IgA to type 9V.
luded that the nebuliser delivered respirable vaccine at a particle
ize consistent with alveolar deposition.
.4. Serum IgG and IgA response to injected and inhaled 23-PPV
Fig. 1 shows serum values for IgG (left hand graphs) and IgA
right hand graphs) speciﬁc to pneumococcal capsular types 1, 9V
nd 14 tested at baseline and 1month after vaccine. The box graphs
how median values for each group on a log scale plotted by vac-
ine group before and after 1 month. Following injected vaccine, a
igniﬁcant increase in serum IgG to all 3 capsular polysaccharide
ypes tested was seen at 1 month. There was a signiﬁcant increase
een in type 1 IgA only.
Following inhaled vaccine, there was no signiﬁcant increase in
ny serum parameter but there was a drop in both IgG and IgA
o type 9V. Baseline values for serum immunoglobulin levels in the
njected and inhaled vaccine groupswere equal as shown in Table 2..5. BAL IgG and IgA response to injected and inhaled 23-PPV
Fig. 2 shows BAL values for IgG (left hand graphs) and IgA (right
and graphs) speciﬁc to pneumococcal capsular types 1, 9V and 14
B
w
b
ccine, a signiﬁcant increase in serum IgG to all three capsular polysaccharide types
ing inhaled vaccine, there was no signiﬁcant increase in any serum parameter but
ested at baseline and 1 month after vaccine. The box graphs show
edianvalues for eachgroupona log scaleplottedbyvaccinegroup
efore and after 1 month. Following injected vaccine, a signiﬁcant
ncrease in BAL IgG to all three capsular polysaccharide types tested
as seen at 1 month. There was no signiﬁcant increase in BAL IgA.
Following inhaled vaccine, there was no signiﬁcant increase in
ny serum parameter but there was a signiﬁcant drop in BAL IgA
o type 9V. Baseline values for BAL immunoglobulin levels in the
njected and inhaled vaccine groupswere equal as shown in Table 2.
. Discussion
We compared the serum and bronchoalveolar lavageresponses
o subcutaneous and inhaled 23-valent pneumococcal capsular
olysaccharide (23-PPV) vaccination in healthy volunteers. The
tudy showed that subcutaneous 23-PPV results in both BAL and
erum immunoglobulin responses, albeit with lower responses in
AL ﬂuid. Inhaled vaccine did not result in BAL or serum responses.
A methodological strength of this study is that serum and BAL
ere directly compared on the same ELISA plate in each subject
efore and after vaccination. In addition, three different vaccine
apsular types recorded the same result. The serum results are con-
5404 S.B. Gordon et al. / Vaccine 26 (2008) 5400–5406
Table 2
Geometric mean immunoglobulin levels with 95% conﬁdence intervals
Injected vaccine Inhaled vaccine
Before After 1 month Before After 1 month
Serum (g/ml)
Type 1 IgG 0.98 (0.53–1.82) 1.95 (1.2–3.2) 0.6 (0.38–1.17) 0.63 (0.36–1.1)
Type 1 IgA 0.88 (0.55–1.39) 5.4 (2.6–11.1) 0.69 (0.5–0.96) 0.67 (0.4–1.2)
Type 9V IgG 0.35 (0.1–1.3) 1.3 (0.7–2.4) 0.2 (0.07–0.6) 0.2 (0.06–0.5)
Type 9V IgA 0.5 (0.26–0.94) 0.97 (0.5–1.7) 0.35 (0.15–0.78) 0.2 (0.06–0.5)
Type 14 IgG 2.75 (1.5–5.0) 8.7 (6.3–12.0) 1.44 (0.56–3.67) 2.0 (0.9–4.0)
Type 14 IgA 0.32 (0.16–0.64) 0.74 (0.4–1.4) 0.23 (0.12–0.42) 0.17 (0.08–0.37)
BAL (ng/ml)
Type 1 IgG 5.0 (3.2–7.9) 9.8 (5.9–16.3) 3.9 (2.3–7.0) 4.4 (2.3–8.4)
Type 1 IgA 28.6 (21.8–37.4) 35.9 (24.1–53.6) 27.6 (18.0–41.0) 25.5 (16.9–38.5)
9.4)
–32)
–51.3
14.5)
s
t
a
i
F
h
a
c
sType 9V IgG 2.7 (1.4–5.5) 5.6 (3.3–
Type 9V IgA 22.7 (15.2–34) 20.1 (13.8
Type 14 IgG 6.2 (2.5–15.4) 23.6 (10.8
Type 14 IgA 8.2 (5.2–12.6) 9.6 (6.4–istent with published data on the response of healthy volunteers
o subcutaneous or intramuscular 23-PPV [26,32]. The BAL data
re novel and show that subcutaneous polysaccharide vaccination
ncreases mucosal levels of IgG and IgA.
c
i
d
ig. 2. Comparison of bronchoalveolar lavage (BAL) responses to injected and inhaled va
and graphs) and IgA (right hand graphs) speciﬁc to pneumococcal capsular types 1, 9V a
nd whisker (5–95%) graphs with outlying values show median values for each group on
apsular polysaccharide types tested was seen at 1 month. There was no signiﬁcant incre
erum parameter but there was a signiﬁcant drop in BAL IgA to type 9V.1.4 (0.7–2.6) 0.8 (0.4–1.7)
17.5 (8.3–37.1) 11.9 (5.4–26.3)
) 3.4 (1.6–7.2) 4.2 (1.4–12.3)
5.6 (3.7–8.7) 4.3 (2.6–7.1)The results of our inhaled 23-PPV study are not completely
onsistent with other published data regarding the same dose of
nhaled 23-PPV delivered to the alveolar space [26,27]. The studies
o agree that inhaled 23-PPV is less effective than injected but in
ccination with 23-valent pneumococcal capsular polysaccharide vaccine. IgG (left
nd 14 were tested in BAL at baseline and 1 month after vaccine. The box (25–75%)
a log scale. Following injected vaccine, a signiﬁcant increase in BAL IgG to all three
ase in BAL IgA. Following inhaled vaccine, there was no signiﬁcant increase in any
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ur series we did not see the increase in serum immunoglobulin
evels in response to inhaled vaccine seen in some subjects (4/10 in
ealthy subjects, 7/10 in COPD patients) previous studies. There are
everal possible explanations for this discrepancy. The ﬁrst is that
hevaccinewasnotdelivered to thealveolar space.Weconsider this
nlikely becausewe have demonstrated that the vaccinewas intact
nd in a respirable fraction and because the subjects experienced
accine-related side-effects similar to those reported in previous
tudies [26]. The dataset available for comparison in this study was
arge enough (n=17) to determine a range of values within the lim-
ts of sensitivity of the assays used and demonstrate the lack of
esponse to inhaled vaccinewith conﬁdence as shown in Fig. 1. Pre-
ious studies reported either smaller numbers (n=4 for serotype
peciﬁc responses) or a pooled polysaccharide-speciﬁc response.
ne biological explanation is that our safety dose of 1/10 vaccine
4h before the full dose may have blunted a possible response. We
onot consider this likely as the duration is too short for a tolerising
esponse and removal of relevant antibodymay have had the oppo-
ite effect. Another biological explanation for the lack of response
s that airway barrier functions including the mucociliary esca-
ator and pre-existing antibody removed the vaccine from these
ealthy volunteers making it unavailable for absorption and sys-
emic response or for local antibody response. Previous studies in
OPD patients [27] compared to healthy controls [26] have shown
igher total immunoglobulin responses in COPD consistent with
ncreased absorption of vaccine through inﬂamedmucosa. Further,
one of our subjects were cigarette smokers and smoke is known
o increase allergen penetration through respiratory mucosa [33].
The ﬁrst novel ﬁnding from this study is that subcutaneous
3-PPV results in increased immunoglobulin levels in BAL. 23-
PV is protective against invasive pneumococcal disease [34] but
oes not protect adults against pneumonia [17], and has been
hown to cause an excess of pneumonia in some studies [15]. One
xplanation for these observations is that mucosal anti-capsular
mmunoglobulin may not be critical in protection against pneu-
onia. Indeed, there are published data to support the hypothesis
hat anti-pneumococcal capsular immunoglobulin, whilst being
ritical in defence against invasive pneumococcal disease, is not
rotective against mucosal infection. First, childhood clearance of
asal colonisation by pneumococci may be CD4 dependent and not
ependent on capsular polysaccharide speciﬁc immunoglobulin
35]. Second, rather than being protective, pneumococcal type-
peciﬁc anti-capsular IgA has been shown to be necessary for
ptimal pneumococcal colonisation of the nasopharynx by an IgA
rotease dependent mechanism [36]. Further, pneumococci col-
nizing the mucosa exhibit the transparent phenotype, in which
he bacteria express relatively little capsule and have prominent
urface proteins, in contrast to bacteria in the bloodstream which
re predominantly heavily capsulated (opaque phase) [37,38]. We
ave reported that opsonisation alters binding and internalization
f pneumococci by human alveolar macrophages, but the numbers
f pneumococci observed to be ingested by alveolar macrophages
n both our experiments [39] and those of others [40,41]weremany
rders of magnitude smaller than the ingestion observed in neu-
rophil experiments [42]. The alveolar macrophage may therefore
e more of a sentinel than an active phagocyte in alveolar defence,
nd opsonisation may not have the critical signiﬁcance that it has
n the defence against invasive pneumococcal disease [43]. Finally,
he observation that HIV infected adults with recent pneumococ-
al infection have higher BAL levels of anti-pneumococcal capsular
mmunoglobulin than HIV infected adults with no recent infec-
ion need not be interpreted as evidence of secondary protection.
igher levels of BAL anti-pneumococcal capsular immunoglobu-
in have also been measured in HIV infected adults than in healthy
ontrol subjects [10], and HIV infected adults have 20–100 times6 (2008) 5400–5406 5405
he incidence of pneumococcal disease seen in healthy adults
44]. In summary, therefore, it may be that BAL immunoglobu-
in is merely a marker of past disease, and of little protective
se.
The secondﬁnding of this studywas that inhaled 23-PPVdid not
esult in enhanced immunoglobulin responses at the mucosal sur-
ace. The pulmonarymucosal surface is carefully regulated to avoid
xcess inﬂammation in response to inhaled antigens [45,46]. If
nti-capsular immunoglobulin is not protective as discussed above,
he lack of response observed in this study would be an appro-
riate immunological response. Upper airway responses were not
ssessed in this study but a comparison of upper and lower air-
ay responses to pneumococcal carriage and vaccine antigens is in
rogress in our laboratory.
Animal studies have shown effective mucosal responses to
hole cell vaccine and to some pneumococcal protein anti-
ens but these studies have been conﬁned to models where the
pper airway architecture and defence is quite different to the
uman. In this study, the lack of local response to polysaccha-
ide antigen is not all that surprising given that polysaccharide
esponses are normally initiated in themarginal zone of the human
pleen.
Prevention of pneumococcal pneumonia remains an important
lobal objective. A mucosal vaccine is attractive for the prevention
f pneumonia as the known immunological compartmentalization
f the pulmonary mucosa gives inhaled vaccination a plausible
mmunological basis in addition to the attractions of needle-free
accination [47]. This study helps in the development of an inhaled
accine in several ways. First, the importance of anti-capsular anti-
ody at the mucosal surface has been questioned and is worthy
f further study. Future inhaled vaccines should perhaps target
he pneumococcal surface proteins, and in particular those that
acilitate mucosal colonisation [48]. Second, this study has demon-
trated that a safe and rigorous comparison of injected and inhaled
accine was possible using BAL immunoglobulin as a marker of
ucosal immunity.
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